Prokalsitonin Seviyesinin COVID-19 Enfeksiyonun Şiddetiyle İlişkisi

Öz

Alt solunum yolu enfeksiyonlarının bakteriyel ve viral etiyolojilerini ayırt etmek için sıklıkla serum prokalsitonin (PCT) düzeyi değerlendirilmesine ihtiyaç duyulur. Çünkü bu belirteç enflamatuar bir durum veya bakteriyel bir enfeksiyon yoksa saptanamayacak kadar düşük düzeydedir. COVID-19 enfeksiyonu sırasında, PCT’nin şüpheli ve doğrulanmış COVID-19 vakalarında hastalığın tanısı için güvenilir veya yararlı bir test olup olmadığı tartışmalıdır. Bu derlemenin amacı, COVID-19 vakalarında PCT’nin klinik olarak yararlı bir test olup olmadığının incelenmesidir.

Anahtar Kelimeler

• COVID-19
• prognoz
• prokalsitonin
• enflamasyon

The Relationship of Procalcitone Level with the Severity of COVID-19 Infection

Öz

Procalcitonin (PCT) level is often evaluated to distinguish bacterial and viral etiologies of lower respiratory tract infections because this marker is undetectable in the absence of an inflammatory condition or bacterial infection. During COVID-19 infection, it is controversial whether PCT is a reliable or useful test for diagnosing the disease in suspected and confirmed cases of COVID-19. The purpose of this review is to examine whether PCT is a clinically useful test in COVID-19 cases.

Anahtar Kelimeler

• COVID-19
• prognosis
• procalcitonin
• inflammation

Kaynakça

1. Bernard Stoecklin S, Rolland P, Silue Y, Alexandra M, Christine C, Anne S, et al. First cases of coronavirus disease 2019 (COVID‐19) in France:surveillance, investigations and control measures, January 2020. Eurosurveillance. 2020;25: 2000094.
2. Wu D, Wu T, Liu Q, Yang Z. The SARS‐CoV‐2 outbreak: what we know. Int J Infect Dis. 2020;94:44–48.
3. Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Therapeutic Advances in Respiratory Disease. 2020;14:175346662093717.
4. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019(COVID-19) : A meta-analysis, Clinica Chimica Acta.2020;505:190-191.
5. Lippi G, Cervellin G. Procalcitonin for diagnosing and monitoring bacterial infections: for or against?, Clinical Chemistry and Laboratory Medicine. 2018;56(8):1193-1195.
6. Liu F, Lin Li, MengDa Xu, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. Journal of Clinical Virology. 2020;127(2020):1-5.
7. Xu JB, Xu C, Zhang RB, Wu M, Pan CK, Li XJ, et al. Associations of procalcitonin, C‑reaction protein and neutrophil‑to‑lymphocyte ratio with mortality in hospitalized COVID‑19 patients in China. Scientific Reports. 2020;10:150-158.
8. Krause M, Douin DJ, Tran TT, Fernandez Bustamante A, Aftab M, Bartels K. Association between procalcitonin levels and duration of mechanical ventilation in COVID-19 patients. PLoS ONE. 2020;15(9):e0239174.

9. Heesom L, Rehnberg L, Nasim-Mohi M, Jackson AIR, Celinski M, Dushianthan A, et al. Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care. Journal of Global Antimicrobial Resistance. 2020;22(2020):782–784.
10. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.
11. Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. Journal of Clinical Virology. 2020;104364.
12. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents. 2020;56(2):106051.
13. Qian GQ, Yang NB, Ding F, Ma AHY, Wang ZY, Shen YF, et al. Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series. QJM. 2020;113(7):474-481.
14. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020;92(7):791-796.
15. Liu ZM, Li JP, Wang SP, Chen DY, Zeng W, Chen SC, et al. Association of procalcitonin levels with the progression and prognosis of hospitalized patients with COVID-19. Int J Med Sci. 2020;17(16):2468-2476.
16. Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J. 2020;133:1032–1038.
17. Cravedi P, Mothi SS, Azzi Y, Haverly M, Farouk SS, Pérez-Sáez MJ, et al. COVID‐19 and kidney transplantation: Results from the TANGO International Transplant Consortium. ASTS. 2020;20(11):3140-3148.
18. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney International. 2020;97(5):829-838.
19. Lo IL, Lio CF, Cheong HH, Lei CI, Cheong TH, Zhong X, et al. Evaluation of SARSCoV- 2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau. Int J Biol Sci. 2020;16:1698–1707.
20. Ou M, Zhu J, Ji P, Li H, Zhong Z, Li B, et al. Risk factors of severe cases with COVID-19: a meta-analysis. Epidemiol Infect. 2020;148-175.
21. Ghahramani S, Tabrizi R, Lankarani KB, Kashani SMA, Rezaei S, Zeidi N, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis. Eur J Med Res. 2020;25(1):30.
22. Li J, He X, Yuanyuan Y, Zhang W, Li X, Zhang Y, et al. Meta-analysis investigating the rela- tionship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) pneumonia. Am J Infect Control. 2021 Jan; 49(1): 82–89.
23. Elshazli RM, Toraih EA, Elgaml A, El-Mowafy M, El-Mesery M, Amin MN, et al. Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patients. PLoS One. 2020;15(8):e0238160.
24. Akbari H, Tabrizi R, Lankarani KB, Aria H, Vakili S, Asadian F, et al. The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019(COVID-19) : A systematic review and meta-analysis. Life Sci. 2020;258:118167.
25. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019(COVID-19) : a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021-1028.